At the forefront of cancer treatment, scientists are continually exploring new targets and therapeutic strategies to address this global health challenge. B7-H3 (CD276), a type I transmembrane glycoprotein, has garnered significant attention due to its overexpression in a wide range of human cancers. Initially believed to function as a T-cell costimulatory molecule, B7-H3 has since been found to possess complex immunomodulatory properties, capable of both promoting and suppressing immune respons

The mRNA therapeutics market has experienced explosive growth over the past few years. According to estimates by QY Research, the global mRNA therapeutics market reached a total sales value of RMB 248.4 billion (approx. USD 35 billion) in 2023. Preventive mRNA vaccines are projected to achieve a 20% penetration rate in the USD 50.3 billion vaccine market by 2025, corresponding to a market size of USD 10.1 billion. Meanwhile, mRNA cancer vaccines are expected to reach a 0.5% penetration rate by 2

June 15, 2025 Results from the EPCORE® NHL-2 trial show investigational treatment with epcoritamab in combination with rituximab, ifosfamide, carboplatin, and etoposide (R-ICE) led to an overall response rate (ORR) of 87 percent and a complete response (CR) rate of 65 percent in patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) Data further demonstrates the potential of epcoritamab in combination with salvage chemoimmunotherapy to increase the proportion of patien

June 12, 2025 -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced new preclinical data on the use of Purified Cortrophin Gel (repository corticotropin injection USP) (Cortrophin Gel) in a mouse model of murine collagen-induced inflammatory arthritis. “In a preclinical model of murine collagen-induced arthritis, repository corticotrophin injection attenuated joint swelling in mice, and decreased inflammatory cytokine response without causing additional bone turnover

Significant and clinically meaningful improvement in pain, function, and other outcomes in people with knee osteoarthritis Rapid onset of action observed Improvement in function out of proportion to pain-relieving effects First-in-class novel biologic under development as non-addictive pain treatment June 12, 2025 -- Levicept Ltd, a biotechnology company focused on the development of LEVI-04, a first-in-class treatment for osteoarthritis, is to present new data from its large-scale Phase II tr

Results demonstrate potential of Company’s clustering antibody approach to address key challenges in HHT disease manifestations: restoring ALK1-mediated cellular signaling, preventing and reversing arteriovenous malformations, and preventing HHT-associated anemia Groundbreaking preclinical profile of Diagonal’s bispecific clustering antibodies supports advancement of lead program, DIAG723, in HHT and PAH June 12, 2025 -- Diagonal Therapeutics, a biotechnology company focused on correcting dysr

Nav1.8 inhibitors hold significant economic value and exhibit promising development trends in the global analgesics market. In 2022, the global market size for analgesic drugs reached approximately USD 91.14 billion, and it is projected to approach USD 90 billion by 2028. In China, the analgesics market was valued at approximately RMB 122.6 billion, with the expectation that China will become the largest and fastest-growing pain treatment market worldwide over the next decade. As a novel class o

Stockholders overwhelmingly approved liquidation and dissolution of the Company at the June 5, 2025 Annual Meeting Initial distribution currently expected in the range between approximately $5.30 and $5.35 per share of common stock, expected in the third quarter of 2025 THB335 demonstrated 85% serum tryptase reduction with an encouraging safety profile in an additional Phase 1 cohort evaluating 100mg dose with new drug product capsule formulation Company initiating a sale process of THB335 June

77% of patients (150 mg Q4W) treated with barzolvolimab who had angioedema at baseline were angioedema free at Week 52 Data further support barzolvolimab clinical benefit to patients with CSU June 14, 2025 -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced data demonstrating that barzolvolimab profoundly improves angioedema at 52 weeks in the Company’s Phase 2 clinical trial in chronic spontaneous urticaria (CSU). Angioedema, characterized by swelling of the deeper dermal layers of t

– 26% (20/77) CR+CRh rate and 48% (37/77) ORR in efficacy-evaluable pivotal R/R mNPM1 AML population – – Robust responses observed across subgroups, regardless of co-mutations, number of prior lines of therapy, or prior venetoclax, within efficacy-evaluable pivotal R/R mNPM1 AML population – – 60% (3/5) ORR in Ph 1 patients with R/R NUP98r AML – June 12, 2025 -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today ann